ReviewInfectious disease clinics of North America2022
Laboratory Diagnosis for SARS-CoV-2 Infection.
Review in Infectious disease clinics of North America, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- No evidence of MMR induced trained immunity to prevent SARS COV2: results from a multi-centre RCT.Frontiers in immunology · 2025Trial
- Article
- Internationally standardized respiratory viral load testing with limited resources: A derivative-of-care calibration strategy for SARS-CoV-2.Influenza and other respiratory viruses · 2024Article
- [Concordance between GeneXpert and Life Real Detection Kit in the diagnosis of acute respiratory infections].Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2023Article
- Evaluation of a novel lyophilized-pellet-based 2019-nCoV nucleic acid detection kit for the diagnosis of COVID-19.PloS one · 2023Article
- Expert consensus on the diagnosis and treatment of severe and critical coronavirus disease 2019 (COVID-19).Journal of intensive medicine · 2022Article
- Distinct Molecular Mechanisms Characterizing Pathogenesis of SARS-CoV-2.Journal of microbiology and biotechnology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The optimal diagnostic test for SARS-CoV-2 infection should be selected based on a patient's clinical syndrome and presentation in relation to symptom onset. Molecular testing, most often reverse-transcriptase polymerase chain reaction, offers the highest sensitivity and specificity during acute infection, whereas antigen testing can also be useful for acute diagnosis when rapid turnaround of results is necessary or if molecular testing is unavailable. Serologic testing is often reserved for identifying individuals with prior or late COVID-19 infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.